EG24076A - Mesylate dihydrate salts of 5-(2-4(1,2 benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one - Google Patents

Mesylate dihydrate salts of 5-(2-4(1,2 benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one

Info

Publication number
EG24076A
EG24076A EG37997A EG37997A EG24076A EG 24076 A EG24076 A EG 24076A EG 37997 A EG37997 A EG 37997A EG 37997 A EG37997 A EG 37997A EG 24076 A EG24076 A EG 24076A
Authority
EG
Egypt
Prior art keywords
benzisothiazol
indol
piperazinyl
dihydro
chloro
Prior art date
Application number
EG37997A
Other languages
English (en)
Inventor
Frank R Busch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG24076A publication Critical patent/EG24076A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
EG37997A 1996-05-07 1997-05-04 Mesylate dihydrate salts of 5-(2-4(1,2 benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one EG24076A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
EG24076A true EG24076A (en) 2008-05-11

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
EG37997A EG24076A (en) 1996-05-07 1997-05-04 Mesylate dihydrate salts of 5-(2-4(1,2 benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one

Country Status (40)

Country Link
US (1) US6245765B1 (enExample)
EP (1) EP0918772B1 (enExample)
JP (1) JP3494659B2 (enExample)
KR (1) KR100333215B1 (enExample)
CN (1) CN1091769C (enExample)
AP (1) AP765A (enExample)
AR (1) AR007004A1 (enExample)
AT (1) ATE278689T1 (enExample)
AU (1) AU731267B2 (enExample)
BG (1) BG63544B1 (enExample)
BR (1) BR9709889A (enExample)
CA (1) CA2252898C (enExample)
CO (1) CO4940466A1 (enExample)
CZ (1) CZ289215B6 (enExample)
DE (1) DE69731094T2 (enExample)
DK (1) DK0918772T3 (enExample)
DZ (1) DZ2222A1 (enExample)
EA (1) EA001190B1 (enExample)
EG (1) EG24076A (enExample)
ES (1) ES2229342T3 (enExample)
GT (1) GT199700052A (enExample)
HR (1) HRP970236B1 (enExample)
ID (1) ID16867A (enExample)
IL (1) IL126591A (enExample)
IS (1) IS2080B (enExample)
MA (1) MA24171A1 (enExample)
MY (1) MY119997A (enExample)
NO (1) NO312514B1 (enExample)
NZ (1) NZ332218A (enExample)
OA (1) OA10909A (enExample)
PL (1) PL188330B1 (enExample)
PT (1) PT918772E (enExample)
SI (1) SI0918772T1 (enExample)
SK (1) SK282837B6 (enExample)
TN (1) TNSN97074A1 (enExample)
TR (1) TR199802240T2 (enExample)
TW (1) TW491847B (enExample)
UA (1) UA46840C2 (enExample)
WO (1) WO1997042191A1 (enExample)
ZA (1) ZA973876B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
AU2001258690A1 (en) * 2000-06-02 2001-12-11 Pfizer Products Inc. S-methyl-dihydro-ziprasidone for treatment of psychiatric and ocular disorders
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
EP1633400A2 (en) * 2003-05-16 2006-03-15 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
EP1546146A1 (en) 2003-06-03 2005-06-29 Teva Pharmaceutical Industries Limited POLYMORPHIC FORMS OF ZIPRASIDONE HCl AND PROCESSES FOR THEIR PREPARATION
CA2543805A1 (en) 2003-10-24 2005-05-06 Gideon Pilarsky Processes for preparation of ziprasidone
EP1753460A2 (en) * 2004-05-11 2007-02-21 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
AU2005307797B2 (en) * 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
CA2591670A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
CN101677568A (zh) * 2007-05-18 2010-03-24 赛多斯有限责任公司 齐拉西酮制剂
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
CN107595771A (zh) * 2010-10-18 2018-01-19 大日本住友制药株式会社 注射用缓释制剂
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
IL126590A (en) 1996-05-07 2001-11-25 Pfizer Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it

Also Published As

Publication number Publication date
CZ289215B6 (cs) 2001-12-12
SK282837B6 (sk) 2002-12-03
SI0918772T1 (en) 2005-02-28
UA46840C2 (uk) 2002-06-17
ID16867A (id) 1997-11-20
JPH11509867A (ja) 1999-08-31
AU2174797A (en) 1997-11-26
CA2252898C (en) 2003-04-08
TW491847B (en) 2002-06-21
IS4874A (is) 1998-10-20
KR100333215B1 (ko) 2002-06-20
EA199800912A1 (ru) 1999-04-29
PL329884A1 (en) 1999-04-12
MA24171A1 (fr) 1997-12-31
ATE278689T1 (de) 2004-10-15
BG102892A (en) 1999-09-30
AP765A (en) 1999-09-17
OA10909A (en) 2001-10-26
AU731267B2 (en) 2001-03-29
EA001190B1 (ru) 2000-12-25
AP9700976A0 (en) 1997-07-31
PL188330B1 (pl) 2005-01-31
IL126591A0 (en) 1999-08-17
SK150898A3 (en) 2000-02-14
DE69731094T2 (de) 2006-02-23
CN1091769C (zh) 2002-10-02
BG63544B1 (bg) 2002-04-30
NZ332218A (en) 2005-02-25
TR199802240T2 (enExample) 1999-02-22
AR007004A1 (es) 1999-10-13
MY119997A (en) 2005-08-30
PT918772E (pt) 2004-12-31
NO985194L (no) 1998-11-06
NO312514B1 (no) 2002-05-21
HRP970236A2 (en) 1998-06-30
CO4940466A1 (es) 2000-07-24
ZA973876B (en) 1998-11-06
NO985194D0 (no) 1998-11-06
DE69731094D1 (de) 2004-11-11
CN1216991A (zh) 1999-05-19
US6245765B1 (en) 2001-06-12
EP0918772A1 (en) 1999-06-02
CA2252898A1 (en) 1997-11-13
HRP970236B1 (en) 2002-12-31
IS2080B (is) 2006-02-15
BR9709889A (pt) 1999-08-10
GT199700052A (es) 2001-08-29
CZ349398A3 (cs) 1999-09-15
DK0918772T3 (da) 2005-01-10
IL126591A (en) 2001-11-25
TNSN97074A1 (fr) 2005-03-15
KR20000010824A (ko) 2000-02-25
DZ2222A1 (fr) 2002-12-03
EP0918772B1 (en) 2004-10-06
WO1997042191A1 (en) 1997-11-13
HK1017892A1 (en) 1999-12-03
JP3494659B2 (ja) 2004-02-09
ES2229342T3 (es) 2005-04-16

Similar Documents

Publication Publication Date Title
AP9700976A0 (en) Mesylate dihydrate salts of 5- (2- (4- (1,2- benzisothiazol-3-YL)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one
EG24401A (en) Mesylate. Trihydrate of. 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-ine
PL380733A1 (pl) Pochodne 3, 3-difenylopropyloamin, sposoby ich wytwarzania, ich zastosowanie medyczne oraz kompozycja farmaceutyczna
HUP9903072A3 (en) 5,7-dihydroxy-chroman-4-on derivatives as immuno suppressive agents
HUP0104646A3 (en) Fused 1,2,4-thiadiazine derivatives, their preparation and use
FR14C0044I2 (fr) Derives de 3-(2-oxo- 1,3']bipyrrolidinyl-3-ylidenemethyl)-cephemes
FR2767677B1 (fr) Microkeratome pour chirurgie optalmologique
ZA987304B (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1H-indole derivatives.
ATE266637T1 (de) 3,3-biarylpiperidin- und 3,3- biarylmorpholinderivate
IL137518A0 (en) Derivatives of 1,2,4-oxadiazolone
ZA200006206B (en) Benzazole compounds and their use.
HU9202914D0 (en) 4-(4-(4-hydroxiphenyl)-1-piperazinyl)-5-methyl-3h-1,2,4-triazole-3-one derivatives
IL135256A0 (en) 2- substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d)
PL344978A1 (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use
GB9706730D0 (en) 2-[(3-substituted)-5-Isoxazolymethylaminojalkanamid derivatives
GB9714303D0 (en) 5-(3-phenyl-3-oxo-propyl)-1H-tetrazole derivatives
NZ300041A (en) 2-(2,3,5,6-tetrafluoropyridin-4-yl)-1,2,5-thiazolidin-3-one 1,1-dioxide derivatives
NZ301453A (en) 4-(substituted phenyl),4-(substituted carboxyl, carboxylamide or alkyl)-cyclohexan-1-one derivatives and medicaments
HUP9802876A3 (en) Process for producing 2-(methylsulfonyl)-5-(trifluoromethyl)-1,3,4-thiadiazole
AU9029898A (en) 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives
NO996392D0 (no) Angiogenese-inhiberende 5-substituerte-1,2,4-tiadiazolyl- derivater
GB9610963D0 (en) 2-[(3-substituted)-5-isoxazolymethylamino]alkanamide derivatives
SI1140835T1 (en) 3,3-biarylpiperidine and 2,2-biarylmorpholine derivatives
ZA956538B (en) Benzimidazole derivatives.
TW317866U (en) Improved wet tissue conveying and cutting configuration for wet tissue supplying machine